Epidemiological Significance
The disease is globally distributed; there are virtually no regions free from the circulation of this pathogen. The primary target and main risk group are young children, predominantly between six months and two years of age. Within this age cohort, the pathology manifests most aggressively.
A critical global health concern remains the exceptionally high mortality rate associated with this infection, with approximately one million deaths registered annually. The leading cause of death in pediatric patients is severe dehydration resulting from profound diarrhea, which rapidly exhausts the child's physiological reserves.
Pathogenesis and Localization
The mechanism of disease development is closely linked to the virus's marked tropism for small intestine tissues. Upon entering the host organism, the pathogen reaches the duodenum, where the active replication phase begins. The virus actively multiplies within the mucosal epithelial cells (enterocytes), inevitably leading to structural destruction and subsequent massive cell death.
The principal pathogenicity factor is the non-structural viral protein NSP4. This protein acts as a true enterotoxin within the human intestinal lumen. The toxic action of the NSP4 protein triggers a cascade of pathophysiological reactions resulting in massive secretory diarrhea.
Clinical Presentation
Clinical manifestations develop acutely and are characterized by prominent digestive tract symptoms. Patients suffer from recurrent vomiting and severe abdominal pain.
The leading and most dangerous symptom is debilitating diarrhea: the frequency of bowel movements can reach 10 to 15 times per day. Despite the alarming intensity of symptoms, the duration of acute manifestations is strictly limited in time, typically lasting only one to two days.
Laboratory Diagnostics
To accurately confirm the diagnosis, a comprehensive approach is applied in laboratory practice, including three main directions:
- Virological method (virus detection). Fecal filtrate is used as the optimal test material. This substrate is chosen because virion concentrations reach exceptionally high values—up to $10^{10}$ particles per microliter. Identification methods include immune electron microscopy, enzyme-linked immunosorbent assay (ELISA), complement fixation test (CFT), neutralization test, immunofluorescence assay (IFA), co-agglutination, and specific RNA probes.
- Serological method. The objective is to detect a diagnostically significant rise in specific antibody titers in blood serum. This process is evaluated dynamically during the 3rd to 8th week from disease onset. Serological tools include ELISA, CFT, indirect hemagglutination assay (IHA), neutralization test, and immunofluorescence.
- Molecular-genetic method. Based on reverse transcription-polymerase chain reaction (RT-PCR).
Treatment and Prevention
Specific etiotropic therapy is not used for this pathogen; treatment is purely supportive and aims to maintain vital body functions.
Non-specific prophylaxis plays a monumental role, relying strictly on basic sanitary and hygienic standards, including thorough monitoring of water supply and sewage systems.
To reliably induce immunity, specific prophylaxis has been developed. Live oral vaccines produced from attenuated (laboratory-weakened) viral strains are successfully used in medical practice.